Plus Therapeutics Announces Selection of "Rhenium (186Re) Obisbemeda" as International Non-Proprietary Name for 186RNL (GlobeNewswire) - Oct 26, 2022 - "Plus Therapeutics...announced that the World Health Organization's (WHO) International Non-proprietary Name (INN) Expert Committee has selected the non-proprietary name 'Rhenium (186Re) obisbemeda' for the Company's lead investigational targeted radiotherapeutic, formerly known as 186RNL. Going forward, Plus Therapeutics will use Rhenium (186Re) obisbemeda in place of 186RNL."
Commercial • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|